EUVIMEDEUVIMED entdecken
Crossref

TREM1 / DAP12 based novel multiple chain CAR‐T cells targeting DLL3 show robust anti‐tumour efficacy for small cell lung cancer

Fengqi Nie, Yuli Chen, Yanming Hu, Peng Huang, Xuefei Shi, Jingsheng Cai, Mantang Qiu iD, Enxiu Wang, Kaihua Lu, Ming Sun iD

Immunology · 2024

DOI: 10.1111/imm.13776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Fengqi Nie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC), recognized as the most aggressive subtype of lung cancer, presents an extremely poor prognosis. Currently, patients with small cell lung cancer face a significant dearth of effective alternative treatment options once they experience recurrence and progression after first‐line therapy. Despite the promising efficacy of immunotherapy, particularly immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC) and various other tumours, its impact on significantly enhancing the prognosis of SCLC patients remains elusive. DLL3 has emerged as a compelling target for targeted therapy in SCLC due to its high expression on the membranes of SCLC and other neuroendocrine carcinoma cells, with minimal to no expression in normal cells. Our previous work led to the development of a novel multiple chain chimeric antigen receptor (CAR) leveraging the TREM1 receptor and DAP12, which efficiently activated T cells and conferred potent cell cytotoxicity. In this study, we have developed a DLL3‐TREM1/DAP12 CAR‐T (DLL3‐DT CAR‐T) therapy, demonstrating comparable anti‐tumour efficacy against SCLC cells in vitro. In murine xenograft and patient‐derived xenograft models, DLL3‐DT CAR‐T cells exhibited a more robust tumour eradication efficiency than second‐generation DLL3‐BBZ CAR‐T cells. Furthermore, we observed elevated memory phenotypes, induced durable responses, and activation under antigen‐presenting cells in DLL3‐DT CAR‐T cells. Collectively, these findings suggest that DLL3‐DT CAR‐T cells may offer a novel and potentially effective therapeutic strategy for treating DLL3‐expressing SCLC and other solid tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveAdaptor Proteins, Signal TransducingMembrane ProteinsXenograft Model Antitumor AssaysTriggering Receptor Expressed on Myeloid Cells-1HumansAnimalsMiceCell Line, TumorIntracellular Signaling Peptides and ProteinsT-LymphocytesMice, SCIDFemale

Stichwörter der Autor:innen

CAR‐TDAP12DLL3SCLCTREM1

Substanzen

Receptors, Chimeric AntigenAdaptor Proteins, Signal TransducingDLL3 protein, humanMembrane ProteinsTriggering Receptor Expressed on Myeloid Cells-1Intracellular Signaling Peptides and ProteinsTYROBP protein, human

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Oncology, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, China.
  • Suzhou Cancer Center Core Laboratory, Suzhou Municipal Hospital, Gusu School, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
  • Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, Zhejiang, China.
  • Huzhou Key Laboratory of Precision Diagnosis and Treatment in Respiratory Diseases, Huzhou Central Hospital, Huzhou, Zhejiang, China.
  • Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Mantang Qiu, Ming Sun

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi Province
  • Natural Science Foundation of Jiangsu Province
  • The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School
  • Peking University People's Hospital Research and Development Founds
  • Natural Science Foundation of Guangxi Zhuang Autonomous Region

Zitieren

APA

Nie, F., Chen, Y., Hu, Y., Huang, P., Shi, X., Cai, J., Qiu, M., Wang, E., Lu, K., & Sun, M. (2024). TREM1 / DAP12 based novel multiple chain CAR‐T cells targeting DLL3 show robust anti‐tumour efficacy for small cell lung cancer. Immunology. https://doi.org/10.1111/imm.13776

Vancouver

Nie F, Chen Y, Hu Y, Huang P, Shi X, Cai J, et al. TREM1 / DAP12 based novel multiple chain CAR‐T cells targeting DLL3 show robust anti‐tumour efficacy for small cell lung cancer. Immunology. 2024. doi:10.1111/imm.13776

BibTeX
@article{Nie2024,
  author = {Nie, Fengqi and Chen, Yuli and Hu, Yanming and Huang, Peng and Shi, Xuefei and Cai, Jingsheng and Qiu, Mantang and Wang, Enxiu and Lu, Kaihua and Sun, Ming},
  title = {TREM1 / DAP12 based novel multiple chain CAR‐T cells targeting DLL3 show robust anti‐tumour efficacy for small cell lung cancer},
  journal = {Immunology},
  year = {2024},
  doi = {10.1111/imm.13776}
}
Kostenlos starten →